Table 2 Ongoing and planned combination clinical trials involving venetoclax
Combined drugs | Disease state(s) | Clinicaltrials.gov identifier | Phase |
|---|---|---|---|
Azacitidine + venetoclax | Elderly, previously untreated AML | NCT03466294 | II |
LDAC + venetoclax | Treatment-naïve AML | NCT02287233 | I/II |
LDAC + venetoclax vs LDAC + placebo | Elderly; treatment-naïve AML | NCT03069352 | III |
Cobimetinib (MEK inhibitor) + venetoclax Idasanutlin (HDM inhibitor) + venetoclax | Elderly RR AML | NCT02670044 | I |
Cobimetinib (MEK inhibitor) + venetoclax Idasanutlin (MDM inhibitor) + venetoclax | RR AML | NCT02670044 | I |
Dinaciclib + venetoclax | RR AML | NCT03484520 | I |
Alvocidib + venetoclax | RR AML | NCT03441555 | I |
Gilteritinib (FIT3 inhibitor) + venetoclax | RR AML | (NCT03625505) | I |
Quizartinib (FIT3 inhibitor) + venetoclax | FLT3 mutated RR AML | (NCT03735875) | Ib/II |
S64315 + venetoclax | AML | NCT03672695 | I |
AZD5991 + venetoclax | RR AML or MDS | NCT03218683 | I/II |
CYC065 (CDK inhibitor) + venetoclax | RR AML or MDS | NCT04017546 | I |
Alvocidib (flavopiridol) + venetoclax | RR AML | NCT03441555 | I |
Obinutuzumab + venetoclax | RR or previously untreated CLL | NCT01685892 | I |
Ibrutinib + obinutuzumab + venetoclax | CLL | NCT03755947 | II |
Acalabrutinib (BTK inhibitor) + venetoclax | Newly diagnosed CLL | NCT03868722 | II/III |
Acalabrutinib + obinutuzumab + venetoclax | CLL | NCT03580928 | II |
Zanubrutinib (BTK inhibitor) + obinutuzumab + venetoclax | Previously untreated CLL or SLL | NCT03824483 | II |
Ublituximab + umbralisib + venetoclax | CLL | NCT03801525 | II |
Duvelisib (PI3K inhibitor) + venetoclax | RR CLL or SLL or RS | NCT03534323 | I/II |
Obinutuzumab + venetoclax | RR DLBCL | NCT02987400 | II |
Ibrutinib + rituximab + venetoclax | RR DLBCL | NCT03136497 | I |
Obinutuzumab + polatuzumab vedotin (ADC against CD79b) + venetoclax | RR DLBCL or FL | NCT02611323 | I |
Rituximab + venetoclax | RR FL | NCT02187861 | II |
Obinutuzumab + ibrutinib + venetoclax | RR MCL | NCT02558816 | I/II |
Ibrutinib + venetoclax | RR MCL | NCT02471391 | II |
Ibrutinib + venetoclax vs ibrutinib + placebo | MCL | NCT03112174 | III |
Carfilzomib + dexamethasone + venetoclax | RR MM | NCT02899052 | II |
Bortezomib + dexamethasone + venetoclax vs bortezomib + dexamethasone + placebo | RR MM | NCT02755597 | III |
Pomalidomide + dexamethasone + venetoclax | RR MM | NCT03567616 | II |